Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
Nuformix PLC (NFX.L) Notice of Allowance of Patent in US
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,
Nuformix PLC (NFX.L) Project update – Progress on NXP002 and NXP004
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, post-fund raising, it has started the planned studies on